No Data
No Data
Express News | CHEMOMAB Granted U.S. Patent #12018074: Anti CCL24 (Eotaxin2) Antibodies for Use in the Treatment of Hepatic Diseases
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $7
Roth MKM analyst Jason Wittes maintains $Chemomab Therapeutics(CMMB.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 50.5% and
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Maxim Group analyst Michael Okunewitch maintains $Chemomab Therapeutics(CMMB.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of
Express News | Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its Ccl24-Neutralizing Antibody Cm-101 in Primary Sclerosing Cholangitis
Express News | Chemomab Therapeutics Shares Are Trading Lower. The Company Announced That It Presented Two Scientific Posters Supporting the Clinical Rationale for the Company's Primary Sclerosing Cholangitis Program at EASL 2024
Express News | Chemomab Says It Presented Two Scientific Posters Supporting The Clinical Rationale For Company's Primary Sclerosing Cholangitis Program At EASL 2024, For The Study Of Liver
No Data
Jaguar8 : Super![heart ❤️](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/2764-fe0f.png)